ReviewDiagnostics (Basel, Switzerland)2025
From Innovation to Application: Can Emerging Imaging Techniques Transform Breast Cancer Diagnosis?
Review in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- AI-Assisted Scoring Improves Interobserver Agreement in Breast Cancer Biomarker Evaluation.Cancers · 2026Article
- MMBCFNet: multi modal hybrid deep learning framework for breast cancer detection using MRI, mammography, and ultrasound images.Journal of ultrasound · 2026Article
- Review
- Radioguided Surgery and Axillary Management in Breast Cancer: From Molecular Imaging to 3D Navigation Toward Personalized Treatment.Life (Basel, Switzerland) · 2026Review
- Mapping the research landscape of photoacoustic imaging in breast cancer: a text-based bibliometric analysis.Gland surgery · 2026Article
- Modern Personalized Strategies for Breast Cancer Treatment: Bridging Precision Oncology and Psycho-Oncology.Journal of clinical medicine · 2026Review
- Exploring the clinical value of quantitative ultrasound scoring method in optimizing the classification of breast BI-RADS category 4a nodules in the Tibetan Plateau region.Frontiers in oncology · 2026Article
- Distinct transcriptomic features of tumor and stromal cells in direct contact in luminal and triple-negative breast cancers.Exploration of targeted anti-tumor therapy · 2026Article
- Latent class analysis of conventional ultrasound features: a novel approach to predicting non-response to neoadjuvant chemotherapy in breast cancer.Frontiers in oncology · 2026Article
- Response-adaptive breast cancer care in the grey zones: integrating ER and HER2 targeted PET, FDG PET/CT under immunotherapy, and ctDNA kinetics.Exploration of targeted anti-tumor therapy · 2026Review
- Multi-colorized tint map for distinguishing triple-negative breast cancers from cysts and fibroadenomas based on the tumor margin.Frontiers in oncology · 2026Article
- Article
- Emerging roles of haemostatic proteins as markers of disease progression and prognosis in breast cancer.Exploration of targeted anti-tumor therapy · 2026Review
- Ultrasound-based artificial intelligence for breast lesion classification.Frontiers in oncology · 2026Review
- Survival prediction in triple-negative breast cancer: a Cox model with fairness assessment using ISO/IEC TR 24027:2021 in a MENA cohort.Exploration of targeted anti-tumor therapy · 2026Article
- Exploring the recurrence and metastasis of breast invasive ductal carcinoma based on machine learning and survival analysis.Frontiers in oncology · 2026Article
- HMC-net: a ResNet fused hierarchical multi-scale cross-attention architecture for mammographic breast malignancy recognition incorporating explainable AI.Frontiers in oncology · 2026Article
- Intra- and peritumoral radiomics for predicting equivocal HER2 status of breast cancer on contrast-enhanced mammography.Frontiers in oncology · 2026Article
- Time-dependent diffusion MRI for noninvasive molecular subtype differentiation and biological correlation in breast cancer: emphasizing the emerging three-tier HER2 classification.Frontiers in oncology · 2025Article
- Immunohistochemical predictors of local recurrence in breast carcinoma: development and sensitivity validation of an IHC-based risk score.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.